MSICS Pharma says the funds will expand production, speed clinical trials for PTSD, depression and OCD, and prepare its psilocybin product for global markets| Read More ynet – Business
Israeli psilocybin biotech firm MSICS raises $3.6M for psychedelic drug push
0 Comments